SG165343A1 - Jnk inhibitors for the treatment of endometriosis - Google Patents

Jnk inhibitors for the treatment of endometriosis

Info

Publication number
SG165343A1
SG165343A1 SG201006416-0A SG2010064160A SG165343A1 SG 165343 A1 SG165343 A1 SG 165343A1 SG 2010064160 A SG2010064160 A SG 2010064160A SG 165343 A1 SG165343 A1 SG 165343A1
Authority
SG
Singapore
Prior art keywords
endometriosis
treatment
jnk inhibitors
jnk inhibitor
jnk
Prior art date
Application number
SG201006416-0A
Other languages
English (en)
Inventor
Stephen S Palmer
Selvaraj Nataraja
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SG165343A1 publication Critical patent/SG165343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201006416-0A 2005-07-15 2006-07-12 Jnk inhibitors for the treatment of endometriosis SG165343A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69965805P 2005-07-15 2005-07-15
EP05109447 2005-10-11

Publications (1)

Publication Number Publication Date
SG165343A1 true SG165343A1 (en) 2010-10-28

Family

ID=35709133

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006416-0A SG165343A1 (en) 2005-07-15 2006-07-12 Jnk inhibitors for the treatment of endometriosis

Country Status (11)

Country Link
US (1) US8592414B2 (ja)
EP (1) EP1904181A2 (ja)
JP (1) JP2009509916A (ja)
KR (1) KR20130087052A (ja)
AU (1) AU2006270184B2 (ja)
BR (1) BRPI0613042A2 (ja)
CA (1) CA2611598A1 (ja)
EA (1) EA016437B1 (ja)
MX (1) MX2008000663A (ja)
SG (1) SG165343A1 (ja)
WO (1) WO2007011762A2 (ja)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199028I2 (de) 1983-11-02 2004-07-01 Applied Research Systems Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit.
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US4988679A (en) 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DK0567566T4 (da) 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
EP0727406B1 (de) 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
ATE234839T1 (de) 1998-12-17 2003-04-15 Hoffmann La Roche 4,5-azolo-oxindole
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
CA2354510A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
WO2000075118A1 (en) 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
EP1218369B1 (en) 1999-08-13 2008-07-23 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
NZ517578A (en) 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
DE60140580D1 (de) * 2000-02-25 2009-12-31 Siemens Healthcare Diagnostics Endometriose Marker und Verwendung derselben
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
EP1193267A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1450792B1 (en) 2001-12-07 2006-09-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives for the treatment of scleroderma
JP2005525096A (ja) * 2002-01-09 2005-08-25 ユニバーシティ オブ ローザンヌ Ｊｎｋシグナル伝達経路の細胞浸透性ペプチドインヒビター
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
BRPI0309594A8 (pt) * 2002-04-25 2017-04-11 Applied Res Systems Ars Holding N V Piperazina benzothiazóis como agentes para o tratamento de distúrbios isquêmicos cerebrais ou distúrbios do snc
CN1684583A (zh) 2002-09-25 2005-10-19 明治制果株式会社 缓释农药颗粒剂
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
SI1696909T1 (sl) 2003-09-12 2008-02-29 Serono Lab Derivati benzotiazola za zdravljenje diabetesa
EP1677903B1 (en) 2003-10-30 2012-08-01 Merck Serono SA Process and apparatus for cooling and atomizing liquid or pasty-like substances
RU2253489C1 (ru) * 2004-04-07 2005-06-10 Научный центр акушерства, гинекологии и перинатологии РАМН Способ лечения бесплодия у женщин с наружным генитальным эндометриозом
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
ATE411817T1 (de) * 2004-11-17 2008-11-15 Ares Trading Sa Benzothiazolformulierungen und ihre verwendung

Also Published As

Publication number Publication date
MX2008000663A (es) 2008-03-13
US20090176761A1 (en) 2009-07-09
AU2006270184B2 (en) 2011-09-29
KR20130087052A (ko) 2013-08-05
AU2006270184A1 (en) 2007-01-25
CA2611598A1 (en) 2007-01-25
EP1904181A2 (en) 2008-04-02
EA016437B1 (ru) 2012-05-30
WO2007011762A3 (en) 2007-04-05
BRPI0613042A2 (pt) 2010-12-14
EA200800343A1 (ru) 2008-06-30
JP2009509916A (ja) 2009-03-12
WO2007011762A8 (en) 2007-08-02
WO2007011762A2 (en) 2007-01-25
US8592414B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TW200733976A (en) Method for the treatment of cognitive dysfunction
MY153669A (en) Ocular allergy treatments field of the invention
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
TW200730190A (en) New combination to treat liver fibrosis
MXPA05011501A (es) Combinacion terapeutica de un inhibidor de cox-2 y un inhibidor de aromatasa.
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
ZA200710497B (en) Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
SG165343A1 (en) Jnk inhibitors for the treatment of endometriosis
TW200642688A (en) New use of PDE7 inhibitors
UA89242C2 (ru) Способ лечения эндометриоза с применением ингибитора jnk, которым является производное бензотиазола
NO20080782L (no) JNK-inhibitorer for behandling av endometriose
ECSP088245A (es) Inhibidores pi3k para el tratamiento de endometriosis
WO2008015538A3 (en) Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine
ATE468852T1 (de) Lofexidine zur intraspinalen anwendung
TNSN08062A1 (en) Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin